Stargardt's Macular Dystrophy Clinical Trial
Official title:
A Phase I, Open-Label, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy(SMD)
The purpose of this study is to evaluate the safety and tolerability of RPE cellular therapy in patients with SMD
- to evaluate the safety and tolerability of RPE cellular therapy in patients with SMD - to evaluate the preliminary efficacy of MA09-hPRE in patients with SMD ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02749734 -
Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases
|
Phase 1/Phase 2 | |
Completed |
NCT01345006 -
Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy
|
Phase 1/Phase 2 | |
Completed |
NCT02445612 -
Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients
|
||
Completed |
NCT02941991 -
A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)
|
||
Active, not recruiting |
NCT03364153 -
Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
|
Phase 2 | |
Completed |
NCT01469832 -
Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)
|
Phase 1/Phase 2 |